Jason J. Luke, MD, FACP and Jennifer Wargo, MD, MMSc - Progress and Promise With Immunotherapy in Resectable Melanoma: Exploring New Evidence and Practical Issues With Checkpoint Inhibitors as Adjuvant Therapy


Manage episode 232828755 series 9912
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Go online to PeerView.com/EWW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma is bright, but achieving optimal care will depend on close collaboration between oncologists and surgeons, as well as the identification of patients who are excellent candidates for immune-based adjuvant therapy. In this activity, based on a recent live symposium, experts in oncology get to the heart of why immunotherapy is a rational and potent management strategy for patients with high-risk, resected melanoma, offer insights into the key studies that validated adjuvant immunotherapy in resectable disease, as well as clarify what the evidence from these trials means for the practice of surgical oncology. The panel of leading experts also synthesizes the clinical experience with adjuvant checkpoint inhibition and detail practical patient identification, dosing, and safety considerations that will make a difference in how you manage your patients. Upon completion of this activity, participants should be better able to: Describe the clinical role and rationale for use of immune-based therapy in stage III, resectable melanoma, Cite updated efficacy and safety findings regarding immune checkpoint inhibitors as an adjuvant option in surgically resected melanoma, including high-risk stage III disease, Recommend the use of adjuvant immunotherapy for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.

261 episodes available. A new episode about every 3 days averaging 58 mins duration .